Thyroid tumor-promoting effects of iodine deficiency and iodine excess were investigated in a rodent 2-stage model to estimate an optimal iodine intake range that would not effectively promote development of thyroid neoplasia. Six-week-old male F344 rats were given a single subcutaneous injection of 2,800 mg/kg body weight N-bis(2-hydroxypropyl)-nitrosamine (DHPN) or saline vehicle, maintained on Remington's iodine-deficient diet (21 ± 2 ng/g iodide), and supplemented with various amounts of potassium iodide up to 260 mg/liter in drinking water to generate conditions ranging from severe iodine deficiency to severe iodine excess. In DHPN-treated rats, both conditions significantly increased thyroid follicular tumorigenesis. In DHPN-untreated rats, iodine deficiency produced diffuse thyroid hyperplasia, characterized by small follicles with tall epithelium and reduced colloid, together with a decrease in thyroxine (T4) and an increase in thyroid-stimulating hormone (TSH). On the other hand, iodine excess produced colloid goiter, characterized by large follicles with flat epithelium and abundant colloid admixed with normal or small-sized follicles lined by cpithelium of normal height, together with normal serum T4 and slightly decreased TSH. These effects were directly proportional to the severity of iodine deficiency or extent of iodine excess and suggest that each condition has a different thyroid tumor promotion mechanism. Iodine intakes that showed the least tumor promotion were 2.6 and 9.7 μg/rat/day in this study. Promoting mechanisms and the problem of statistically estimating recommended daily iodine intake range are briefly discussed.
1. Andersen CJ, Keiding NR, and Nielsen AB (1964). False elevation of serum protein-bound-iodine caused by red colored drugs or foods. Scand. J. Clin. Lab. Invest16: 249.
2.
2. Armitage P (1971). Statistical Methods in Medical Research, 2nd ed. John Wiley & Sons, New York, pp. 363–365.
3.
3. Axelrad AA and Leblond CP (1955). Induction of thyroid tumors in rats by a low iodine diet. Cancer8: 339–367.
4.
4. Bagchi N, Shivers B, and Brown TR (1985). Studies on the mechanism of acute inhibition of thyroglobulin hydrolysis by iodine. Acta Endocrinol108: 511–517.
5.
5. Belfiore A, La Rosa GL, Padova G, Sava L, Ippolito O, and Vigneri R (1987). The frequency of cold thyroid nodules and thyroid malignancies in patients from a iodine-deficient area. Cancer60: 3096–3102.
6.
6. Bernstein R, Haugen HF, and Frey H (1975). Thyroid function during erythrosineingestion in doses encountered in therapy with conventional antibiotics. Scand. J. Clin. Lab. Invest35: 49–52.
7.
7. Braverman LE and Ingbar SH (1963). Changes in thyroidal function during adaptation to large dose of iodide. J. Clin. Invest42: 1216–1231.
8.
8. Chiraseveennuprapund P and Rosenberg N (1981). Effect of hydrogen peroxidase-generating systems on the Wolff-Chaikoff effect. Endocrinology109: 2095–2101.
9.
9. Collins TFX and Long EL (1976). Effects of chronic oral administration of erythrosine in the Mongolian gerbil. Food Cosmet. Toxicol14: 233–248.
10.
10. Correa P and Welsh RA (1960). The effect of excess iodine intake on the thyroid gland of the rat. Arch. Pathol70: 247–251.
11.
11. Daniel JW (1962). The excretion and metabolism of edible food colors. Toxicol. Appl. Pharmacol4: 572–594.
12.
12. Dunnett CW (1955). A multiple comparisons procedure for comparing several treatments with a control. J. Am. Stat. Assoc50: 1096–1121.
13.
13. Ermans AM (1978). Disorders of iodine deficiency: Endemic goiter. In: The Thyroid: A Fundamental and Clinical Text, 4th ed., SC Werner and SHIngbar (eds). Harper and Row, Hagerstown, MD, pp. 537–553.
14.
14. Follis RH Jr (1959). Experimental colloid goiter in the hamster. Proc. Soc. Exp. Biol. Med100: 203–206.
15.
15. Franceschi S, Fassina A, Talamini R, Mazzolini A, Vianello S, Bidoli E, Serraino D, and La-Vecchia D (1989). Risk factors for thyroid cancer in northern Italy. Int. J. Epidemiol18: 578–584.
16.
16. Franssila K, Saxen E, Teppo L, Bjamason O, Tulinius H, Normann T, and Ringertz N (1981). Incidence of different morphological types of thyroid cancer in the Nordic countries. Acta Pathol. Microbiol. Scand. A89: 49–55.
17.
17. Gardner DF, Utiger RD, Schwarts SL, Witorsch P, Meyers B, Braverman LE, and Witorsch RJ (1987). Effects of oral erythrosine (2',4',5',7'-tetraiodofluorescein) on thyroid function in normal men. Toxicol. Appl. Pharmacol91: 299–304.
18.
18. Gart JJ, Krewski D, Lee PN, Tarone RE, and Wahrendorf J (1986). Statistical Methods in Cancer Research, Vol. III. The Design and Analysis of Long-term Animal Experiments IARC Scientific Publication No. 79, International Agency for Research on Cancer, Lyon, p. 83.
19.
19. Hansen WH, Davis KJ, Graham SL, Perry CH, and Jacobson KH (1973). Long-term toxicity studies of erythrosine. II. Effects on hematology and thyroxine and protein-bound iodine in rats. Food Cosmet. Toxicol11: 527–534.
20.
20. Haran-Ghera N, Pullar P, and Furth J (1960). Induction of thyrotropin-dependent thyroid tumors by thyrotropes. Endocrinology66: 694–701.
22. Hedinger C (1981). Geographic pathology of thyroid disease. Pathol. Res. Pract171: 285–292.
23.
23. Hedinger C, Williams ED, and Sobin LH (1988). Histologic typing of the thyroid tumours. In: International Histological Classification of Tumours, 2nd ed. World Health Organization, Springer-Verlag, Berlin.
24.
24. Hiasa Y, Kitahori Y, Konishi N, Enoki N, and Fujita T (1983). Effect of varying the duration of exposure to phenobarbital on its enhancement of N-bis(2-hydroxypropyl)nitrosamine-induced thyroid tumorigenesis in male Wistar rats. Carcinogenesis4: 935–937.
25.
25. Iodine nutriture in the United States: Summary of a Conference October 31, 1970 (1970). Food and Nutrition Board, National Academy of Sciences, Washington D.C.
26.
26. Ito A, Watanabe H, Naito M, Aoyama H, Nakagawa Y, and Fujimoto N (1986). Induction of thyroid tumors in (C57BL/6N × C3H/N)F1 mice by oral administration of 9–3',4',5',6'-tetrachlocarboxyphenyl-6-hydroxy-2,4,5,7-tetraiodo-3-isoxanthone sodium (Food Red 105, Rose Bengal B). J. Natl. Cancer Inst77: 277–281.
27.
27. Kanno J, Matsuoka C, Furuta K, Onodera H, Miyajima H, Maekawa A, and Hayashi Y (1990). Tumor promoting effect of goitrogens on the rat thyroid. Toxicol. Pathol18: 239–246.
28.
28. Kimura S, Suwa J, Ito M, and Sato H (1976). Development of malignant goiter by defatted soybean with iodine-free diet in rats. Jpn. J. Cancer Res67: 763–765.
29.
29. Krewski D and van Ryzin J (1981). Dose response models for quantal response toxicity data. In: Statistics and Related TopicsM Csorgo, DA Dawson, JNK Rao, AK Saleh (eds). Elsevier-North Holland Publishing Co., New York, pp. 201–231.
30.
30. Laurberg P and Boye N (1987). Inhibitory effect of various radiographic contrast agents on secretion of thyroxine by the dog thyroid and on peripheral and thyroidal deiodination of thyroxine to triiodothyronine. J. Endocrinol112: 387–390.
31.
31. MacKenzie WF and Boorman GA (1990). Pituitary gland. In: Pathology of the Fischer Rat. Reference and Atlas, GA Boorman, SL Eustis, MR Elwell, CA Montgomery Jr, and WF MacKenzie (eds). Academic Press, Inc.. San Diego, CA, pp. 497–498.
32.
32. Mantel N and Brvan WR (1961). “Safety” testing of carcinogenic agents. J. Natl. Cancer Inst27: 455–470.
33.
33. Martino E, Mariotti S, Aghini-Lombardi F, Lenziardi M, Morabito S, Baschieri L, Pinchera A, Braverman L, and Safran M (1986). Short term administration of potassium perchlorate restores euthyroidism in amiodarone iodine-induced hypothyroidism. J. Clin. Endocrinol. Metab63: 1233–1236.
34.
34. Melmed S, Nademonee K, Reed AW, Hendrickson J, Singh BN, and Hershman JM (1981). Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J. Clin. Endocrinol. Metab53: 997–1001.
35.
35. Morton ME, Chaikoff IL, and Rosenfeld S (1944). Inhibiting effect of inorganic iodide on the formation in vitro of thyroxine and diiodotyrosine by suviving thyroid tissue. J. Biol. Chem154: 381–387.
36.
36. Nagataki S, Shizume K, Nakao K (1970). Alterations in intrathyroidal iodine metabolism in response to chronic iodide administration. Endocrinology87: 1218–1227.
37.
37. Nunez J and Pommier J (1982). Formation of thyroid hormones. Vitam. Horm39: 175–229.
38.
38. Ohshima M and Ward JM (1986). Dietary iodine deficiency as a tumor promoter and carcinogen in male F344/NCr rats. Cancer Res46: 877–883.
39.
39. Okayasu I, Mori W, and Miyagawa N (1973). An autopsy case of congenital goiter. Acta Pathol. Jpn23: 531–537.
40.
40. Pendergrast WJ, Milmore BK, and Marcus SC (1961). Thyroid cancer and thyrotoxicosis in the United States: Their relation to endemic goiter. J. Chronic Dis13: 22–38.
41.
41. Peto R, Pike MC, Day NE, Gray RG, Lee PN, Parish S, Peto J, Richards S, and Wahrendorf J (1980). Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal (IARC Monographs Supplement 2), International Agency Tor Research on Cancer, Lyon, pp. 311–426.
42.
42. Rao RH, McCready VR, and Spathis GS (1986). Iodine kinetic studies during amiodarone treatment. J. Clin. Endocrinol. Metab62: 563–568.
43.
43. Rappaport B, West MN, and Ingbar SH (1975). Inhibitory effect of dietary iodine on the thyroid adenyl cyclase response to thyrotropin in the hypophyseczed rats. J. Clin. Invest56: 516–519.
44.
44. Remington RE (1937). Improved growth in rats on iodine deficient diet. J. Nutrition13: 223–233.
45.
45. Remington RE and Levine H (1936). Studies on the relation of diet to goiter. III. Further observations on a goitrogenic diet. J. Nutrition11: 343–357.
46.
46. Report of the subcommittee for the study of endemic goitre and iodine deficiency of the European Thyroid Association. Goitre and iodine deficiency in Europe (1985). Lanceti: 1289–1292.
47.
47. Ruiz M and Ingbar SH (1983). Effect of erythrosine (2',4',5',7'-tetraiodofluorescein) on the metabolism of thyroxine in rat liver. Endocrinology110: 1613–1617.
48.
48. Savoie JC, Massin JP, Thomopoulos P, and Leger F (1975). Iodine-induced thyrotoxicosis in apparently normal thyroid glands. J. Clin. Endocrinol. Metab41: 685–691.
49.
49. Senior B and Chernoff HL (1971). Iodide goiter in the newborn. Pediatrics47: 510–515.
50.
50. Studer H, Riek M, and Greer H (1979). Multinodular goiter. In: Endocrinology, Vol. 1, L De Groot (ed). Grune and Stratton, New York, pp. 489–499.
51.
51. The 30th Meeting of the Joint FAO/WHO Expert Committee on Food Additives, Rome, 2–11 June1986 (1987). Erythrosine. In: Toxicological Evaluation of Certain Food Additives and Contaminants, WHO Food Additive Series: 21 Cambridge University Press, Cambridge, pp. 81–109.
52.
52. Van Sande J, Grenier G, Willems C, and Dumont JE (1975). Inhibition by iodide of the activation of the thyroid cyclic 3',5'-AMP system. Endocrinology96: 781–786.
53.
53. Vought RL, Brown FA, and Wolff J (1972). Erythrosine: An adventitious source of iodide. J. Clin. Endocrinol. Metab34: 747–752.
54.
54. Wahner HW, Cuello C, Correa P, Uribe LF, and Gaitan E (1966). Thyroid carcinoma in an endemic goiter area, Cali, Colombia. Am. J. Med40: 58–66.
55.
55. Williams ED, Doniach I, Bjarnason O, and Michie W (1977). Thyroid cancer in an iodide rich area. A histopathologic study. Cancer39: 215–222.
56.
56. Wolff J (1969). Iodide goiter and the pharmacologic effects of excess iodide. Am. J. Med47: 101–124.
57.
57. Wolff J and Chaikoff L (1948). Plasma inorganic iodide as a homeostatic regulator of thyroid function. J. Biol. Chem174: 555–564.
58.
58. Wolff J, Chaikoff RC, Goldberg RC, and Meier JR (1949). The temporary nature of the inhibitory action of excess iodide on organic iodine synthesis in the normal thyroid. Endocrinology45: 504–513.
59.
59. Wu S-Y (1983). Thyrotropin-mediated induction of thyroidal iodothyronine monodeiodinase in the dog. Endocrinology112:417–424.
